Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

1.7K
Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
1.7K
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

532
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
532
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

1.4K
Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
1.4K
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests01:27

Atherosclerosis II: Clinical Manifestations and Diagnostic Tests

662
Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
662
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

838
Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
838
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

55
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
55

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Role of Coronary Artery Calcium in Statin Eligibility Based on the American Heart Association's PREVENT Calculator: Insights From MESA.

Journal of the American College of Cardiology·2026
Same author

Metabolic health and cardiovascular outcomes in treated hypertension: a secondary analysis of SPRINT.

Clinical hypertension·2026
Same author

Incidence and risk factors for aortic dissection in a community-based cohorts: The Atherosclerosis Risk in Communities (ARIC) and Multi-Ethnic Study of Atherosclerosis (MESA) studies.

American journal of preventive cardiology·2026
Same author

Prevention of atherosclerotic coronary artery disease in tactical athletes.

American journal of preventive cardiology·2026
Same author

Beyond therapeutic maximalism: Prioritization and personalization in preventive therapies.

Progress in cardiovascular diseases·2026
Same author

Response to: "Absolute cardiovascular risk: the missing denominator in Lp(a)-guided aspirin therapy in primary prevention".

European journal of preventive cardiology·2026

Related Experiment Video

Updated: Mar 6, 2026

A High-Throughput Luciferase Assay to Evaluate Proteolysis of the Single-Turnover Protease PCSK9
08:14

A High-Throughput Luciferase Assay to Evaluate Proteolysis of the Single-Turnover Protease PCSK9

Published on: August 28, 2018

8.7K

PCSK9 and Atherosclerosis - Lipids and Beyond.

Michael D Shapiro1, Sergio Fazio1

  • 1Oregon Health & Science University, Knight Cardiovascular Institute, Center for Preventive Cardiology.

Journal of Atherosclerosis and Thrombosis
|March 18, 2017
PubMed
Summary

Proprotein convertase subtilisin/kexin type 9 (PCSK9) plays a role in cholesterol metabolism. This review explores the direct link between PCSK9 and atherosclerosis, examining plaque biology, inflammation, and epidemiology.

Keywords:
AtherosclerosisHypercholesterolemiaInflammationLipid metabolismLow density lipoproteinProprotein convertase subtilisin/kexin type 9

More Related Videos

Quantitative Analysis and Characterization of Atherosclerotic Lesions in the Murine Aortic Sinus
06:43

Quantitative Analysis and Characterization of Atherosclerotic Lesions in the Murine Aortic Sinus

Published on: December 7, 2013

14.7K

Related Experiment Videos

Last Updated: Mar 6, 2026

A High-Throughput Luciferase Assay to Evaluate Proteolysis of the Single-Turnover Protease PCSK9
08:14

A High-Throughput Luciferase Assay to Evaluate Proteolysis of the Single-Turnover Protease PCSK9

Published on: August 28, 2018

8.7K
Quantitative Analysis and Characterization of Atherosclerotic Lesions in the Murine Aortic Sinus
06:43

Quantitative Analysis and Characterization of Atherosclerotic Lesions in the Murine Aortic Sinus

Published on: December 7, 2013

14.7K

Area of Science:

  • Cardiovascular Biology
  • Lipid Metabolism
  • Molecular Medicine

Background:

  • Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a recently discovered plasma protein linked to cholesterol levels.
  • Therapeutic PCSK9 inhibition is established, but its physiological role requires further investigation.

Purpose of the Study:

  • To review the direct relationship between PCSK9 and atherosclerosis.
  • To synthesize current knowledge on PCSK9's physiological impact on cholesterol metabolism and plaque development.

Main Methods:

  • Analysis of experimental models of plaque biology and inflammation.
  • Review of atherosclerosis imaging studies.
  • Examination of observational epidemiological data.

Main Results:

  • Emerging data suggest a direct link between PCSK9 and atherosclerosis.
  • PCSK9 influences cholesterol metabolism and potentially plaque progression.

Conclusions:

  • The physiological role of PCSK9 in atherosclerosis is an active area of research.
  • Further investigation into PCSK9's direct impact on cardiovascular disease is warranted.